Advances in disease biology and pathophysiology
AL amyloidosis
CAR T cell sand other cellular therapies
Therapy for non-transplant eligible patients
Guidelines in specific clinical situations
Immunotherapy / Bispecific antibodies, Antibody drug conjugates, etc.
Mensural residual disease and disease assessment
Ongoing clinical trials and future trials
Options for refractory myeloma – sequencing of therapy in refractory disease
Outcome prediction and risk assessment
Smoldering myeloma, MGUS and precursor conditions
Treatment guidelines for young and fit patients
Small molecules and preliminary data
Waldenstrom macroglobulinemia
